Floatz logo

Bortezomib

Acquired Hemophilia A

Peking Union Medical College HospitalSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Acquired Hemophilia A cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Peking Union Medical College Hospital
Phase 4BB
Rituximab
Peking Union Medical College Hospital
Phase 4BB
Daratumumab
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
Tak-672
Takeda
Phase 2/3B
Emicizumab
University of Washington
Phase 2B
Obi-1
Baxalta now part of Shire
Phase 2/3CCC
Susoctocog Alfa
Takeda
UnknownD

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative · Phase 2
73 / 100
View asset →
follicular lymphomaDormant
BB
Indicative · Phase 2
71 / 100
View asset →
Waldenstrom macroglobulinemiaActive
BB
Indicative · Phase 2
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →